Immunoglobulins are the major secretory products of the adaptive immune system. Each is
characterized by a distinctive set of glycoforms that reflects the wide variation in the number …

Antibodies constitute the most rapidly growing class of human therapeutics and the second
largest class of drugs after vaccines. The generation of potent antibody therapeutics, which I …

Background Type 1 diabetes mellitus is a T-cell–mediated autoimmune disease that leads to
a major loss of insulin-secreting beta cells. The further decline of beta-cell function after …

Antibodies may be viewed as adaptor molecules that provide a link between humoral and
cellular defence mechanisms. Thus, when antigen-specific IgG antibodies form …

Type 1 diabetes mellitus results from a T-cell mediated autoimmune destruction of the
pancreatic beta cells in genetically predisposed individuals. The knowledge of the …

CD3-specific antibodies have the unique capacity to restore self-tolerance in established
autoimmunity. They induce long-term remission of overt diabetes in nonobese diabetic …

The induction of tolerance is a major goal of immunotherapy. Investigations over the last 20
years have shown that anti-CD3 monoclonal antibodies (mAbs) effectively treat autoimmune …

Many research and clinical applications require large quantities of full-length antibodies with
long circulating half-lives, and production of these complex multi-subunit proteins has in the …

Targeted immunotherapies hold great promise for the treatment and cure of autoimmune
diseases. The efficacy of CD3-specific monoclonal antibody therapy in mice and humans …

During the past decade biologic therapies such as monoclonal antibodies and fusion
proteins have revolutionized the management of rheumatic disease. By targeting key …